Browsing by Author "Psyrri, A."
Now showing items 1-2 of 2
-
Article
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group
Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...
-
Article
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A hellenic cooperative oncology group (HECOG) study
Psyrri, A.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Batistatou, Anna; Bournakis, E.; Timotheadou, E.; Gogas, H.; Aravantinos, Gerasimos; Christodoulou, C.; Makatsoris, T.; Linardou, H.; Pectasides, Dimitrios; Pavlidis, Nicholas; Economopoulos, T.; Fountzilas, George (2012)Background: The ubiquitin-proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression. In the present study, we sought to explore the ...